ATF5 and Alzheimer disease: Our data collected on MCI and AD post-mortem brain samples further support the weaking of UPRmt with the progression of the pathology [70], whereby persistently elevated Atf5 levels parallel no changes on the downstream targets and mostly important are associated with clinically relevant neuropathology.